GlassScriptPhysician profile
Wonestta A Collins
NPI 1417203746
$1,071.58
in general payments reported to CMS, 2019-2025
14 companies · $70.96 in 2025
The $70.96 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $203 · 2020: $100 · 2021: $104 · 2022: $218 · 2023: $294 · 2024: $82.12 · 2025: $70.96.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $447.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $447.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $318.54 | 2019-2023 | |
| Janssen Pharmaceuticals, INC | $285.50 | 2019-2024 | Xarelto |
| Paratek Pharmaceuticals, INC. | $127.71 | 2022-2025 | Nuzyra |
| Vifor Pharma, INC. | $65.75 | 2019-2021 | |
| Abbvie INC. | $54.87 | 2022-2023 | Dalvance, Avycaz |
| Pacira Pharmaceuticals Incorporated | $44.00 | 2019 | |
| Abiomed | $37.90 | 2022 | |
| Ceribell, INC. | $29.48 | 2025 | Pocket Eeg Device |
| Mylan Specialty L.P. | $24.46 | 2023 | Yupelri |
| Allergan, INC. | $24.20 | 2019-2020 | |
| Gilead Sciences, INC. | $17.98 | 2023 | Veklury |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.51 | 2019 | |
| Boston Scientific Corporation | $13.53 | 2023 | Watchman Flx |
| Novartis Pharmaceuticals Corporation | $13.15 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wonestta Collins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.